Baxter International Inc. reported a 10% increase in fourth-quarter sales, reaching $3.5 billion, and a 42% increase in U.S. GAAP earnings per share to $0.47. The results include 19 days of contribution from Hillrom following its acquisition in December 2021. The company's performance reflects strong demand for its medically essential products and the impact of its ongoing transformation.
Fourth-quarter sales increased 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis.
U.S. GAAP earnings per share (EPS) were $0.47, and adjusted EPS was $1.04 for the fourth quarter.
Full-year revenue increased 10% on a reported basis, 7% on a constant currency basis, and 5% on an operational basis.
The acquisition of Hillrom is expected to accelerate top- and bottom-line performance and drive innovation in connected care solutions.
Baxter expects full-year 2022 sales growth of 24% to 25% on a reported basis and adjusted earnings of $4.25 to $4.35 per diluted share. For the first quarter of 2022, the company anticipates sales growth of 24% to 25% on a reported basis and adjusted earnings of $0.79 to $0.82 per diluted share.
Visualization of income flow from segment revenue to net income